In the YO group, variant KRAS was more prevalent in females (807 females [52.2%] vs 739 males [47.8%]; P < .001), while in the LO group, a lower proportion of females (5824 females [55.4%] vs 3997 males [54.7%]; P < .001) had variant KRAS. Adenocarcinomas were the most frequently diagnosed histology type, representing approximately 90% of tumors across age and KRAS status group (YO: 2086 patients with wild-type [90.9%] and 1390 patients with variant [89.9%] KRAS; LO: 9471 patients with wild-type [90.1%] and 6588 patients with variant [90.1%] KRAS). This evidence concerns the gene KRAS and adenocarcinoma.